Phase 2 N=60 Green Tea Lozenges for the Management of Dry Mouth
Xerostomia · Sjogren Syndrome · Dry Mouth
Primary: Change in Salivary Flow From Baseline — 0.17; 0.10; 0.66; 0.04 ml/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=194 A Study to Assess the Effects of an Oral Dietary Supplement on Overall Facial Appearance Among Healthy Adult Women With Existing Skin Damage From Sun Exposure
Photodamaged Skin
Primary: Change From Baseline in Investigator Global Assessment (IGA) of Participant's Overall Facial Appearance at Week 24 — 6.04; 5.81; 0.6; 0.7 units on scale — p=0.358
Phase 3 N=567 Treatment Failure of Chlamydial Infection in Males and Females in Youth Correctional Facilities
Chlamydial Infection
Primary: Assess Microbiological Failure of Recommended Azithromycin and Doxycycline Regimens in Uncomplicated Chlamydia Trachomatis Infection in a Setting Where Repeat Exposure…
Phase 2 N=66 Development of Positive Psychotherapy for Smoking Cessation
Smoking
Primary: 7-day Point Prevalence Smoking Abstinence at 8 Weeks — 40.0; 25.8 percentage of participants abstinent — p=.22
Phase 4 N=7 Tetracaine Compared to Placebo for Reducing Pain With Palivizumab - A Pilot Study
Pain
Primary: To Determine if a Difference in Pain Scale Ratings is Detectable Following Intramuscular Palivizumab Injection That Was Pre-treated With Placebo or Tetracaine. — 7.3…
N/A N=90 DEtermining Accuracy and TrEnding CharacTerization of AF
Atrial Fibrillation
Primary: Assess SJM (St. Jude Medical) Confirm ICM (Implantable Cardiac Monitor) Sensitivity and Positive Predictive Values of AF Episodes of at Least 2 Minutes in Length…
N/A N=100 Chronic Total Occlusion Crossing With the Ocelot System - CONNECT II
Total Atherosclerotic Occlusion of Femoral Artery
Primary: Primary Safety Endpoint — 2 Percent of participants
N/A N=443 Improving Depression Management Through Peer Support
Depression
Primary: Change in Functional Status-Mental Health (MCS) Over 12 Month Period — 32.71; 33.72; 34.77; 36.58 units on a scale — p=<0.05
Phase 4 N=517 Identifying Treatments to Motivate Smokers to Quit
Smoking · Smoking Cessation · Motivation
Primary: Percent Change in Cigarettes Smoked Per Day (CPD) — 38.7; 38.9; 37.4; 40.2 Percent Change in cigarettes per day — p=.98
Phase 2 N=410 Yoga in Treating Sleep Disturbance in Cancer Survivors
Fatigue · Cancer · Sleep Disorders
Primary: Mean Post-Pre Change for the Pittsburgh Sleep Quality Inventory (PSQI) — -1.96; -1.07 units on a scale — p=0.009
Phase 2 N=58 Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: 11-month Survival Rate — 70 percentage of participants
N/A N=25 Mechanisms of Insulin Resistance in Humans
Inflammation · Insulin Resistance
Primary: Insulin Signaling With Lipid Infusion — 0.4334; 0.7276; 0.5264; 0.3534 ratio
Phase 2 N=90 Effects of Acupuncture in the Treatment of Infant Colic
Infant Colic
Primary: Change in Crying Time Per 24 Hour Period. — 220; 212; 230; 186 minutes crying time pr 24 hour
Phase 3 N=744 A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149
Chronic Obstructive Pulmonary Disease
Primary: Trough Forced Expiratory Volume in One Second (FEV1) Following 26 Weeks of Treatment to Demonstrate the Non-inferiority of QVA149 110/50 μg o.d. to…
Phase 2 N=254 Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients
Rheumatoid Arthritis
Primary: ACR Efficacy Criteria — 63; 57; 57; 61 participants